TNFRSF9 and neoplasm: (193) evaluated the combination of anti-PD-1 with anti-LAG3 and anti-CD137 with PD-1 in a mouse model of B16F10 melanoma and showed that simultaneous blockade of PD-1 and CD137 had the most pronounced tumor suppressive effect.